GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ambrx Biopharma Inc (NAS:AMAM) » Definitions » Current Ratio

Ambrx Biopharma (Ambrx Biopharma) Current Ratio : 13.28 (As of Jun. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Ambrx Biopharma Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Ambrx Biopharma's current ratio for the quarter that ended in Jun. 2023 was 13.28.

Ambrx Biopharma has a current ratio of 13.28. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.

The historical rank and industry rank for Ambrx Biopharma's Current Ratio or its related term are showing as below:

AMAM' s Current Ratio Range Over the Past 10 Years
Min: 1.22   Med: 7.02   Max: 13.28
Current: 13.28

During the past 4 years, Ambrx Biopharma's highest Current Ratio was 13.28. The lowest was 1.22. And the median was 7.02.

AMAM's Current Ratio is not ranked
in the Biotechnology industry.
Industry Median: 3.795 vs AMAM: 13.28

Ambrx Biopharma Current Ratio Historical Data

The historical data trend for Ambrx Biopharma's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ambrx Biopharma Current Ratio Chart

Ambrx Biopharma Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Current Ratio
1.22 7.02 7.19 5.44

Ambrx Biopharma Quarterly Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Current Ratio Get a 7-Day Free Trial 9.90 7.19 4.70 5.44 13.28

Competitive Comparison of Ambrx Biopharma's Current Ratio

For the Biotechnology subindustry, Ambrx Biopharma's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ambrx Biopharma's Current Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ambrx Biopharma's Current Ratio distribution charts can be found below:

* The bar in red indicates where Ambrx Biopharma's Current Ratio falls into.



Ambrx Biopharma Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Ambrx Biopharma's Current Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Current Ratio (A: Dec. 2022 )=Total Current Assets (A: Dec. 2022 )/Total Current Liabilities (A: Dec. 2022 )
=90.583/16.66
=5.44

Ambrx Biopharma's Current Ratio for the quarter that ended in Jun. 2023 is calculated as

Current Ratio (Q: Jun. 2023 )=Total Current Assets (Q: Jun. 2023 )/Total Current Liabilities (Q: Jun. 2023 )
=241.413/18.179
=13.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ambrx Biopharma  (NAS:AMAM) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Ambrx Biopharma Current Ratio Related Terms

Thank you for viewing the detailed overview of Ambrx Biopharma's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Ambrx Biopharma (Ambrx Biopharma) Business Description

Traded in Other Exchanges
Address
10975 North Torrey Pines Road, La Jolla, CA, USA, 92037
Ambrx Biopharma Inc is a clinical-stage biologics company focused on discovering and developing a novel class of engineered precision biologics (EPBs) using its proprietary expanded genetic code technology platform that allows incorporating synthetic amino acids (SAAs) into proteins within living cells. Its product pipeline includes ARX788, ARX517, ARX305 among others.
Executives
Cormorant Asset Management, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Margaret Dalesandro director ONCOSEC MEDICAL INCORPORATED, 24 NORTH MAIN STREET, PENNINGTON NJ 08534
Sonja Nelson officer: Chief Financial Officer C/O MOTUS GI HOLDINGS, INC., 1301 EAST BROWARD BOULEVARD, 3RD FLOOR, FT. LAUDERDALE FL 33301
Daniel J. O'connor director, officer: President and CEO C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Abhishek Trehan 10 percent owner WHITELEY CHAMBERS, DON STREET, ST. HELIER Y9 JE2 4TR
Darwin Global Master Fund, Ltd. 10 percent owner C/O OGIER GLOBAL (CAYMAN) LIMITED, 89 NEXUS WAY, CAMANA BAY, GRAND CAYMAN E9 KY1-9009
Paul V Maier director 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Janet Loesberg director C/O AMBRX BIOPHARMA INC., 10975 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
Kate Hermans director C/O AMBRX BIOPHARMA INC., 10975 TORREY PINES ROAD, LA JOLLA CA 92037
Xiaowei Chang director 10975 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
Stephen C. Glover director 108 DOCKSIDE CIRCLE, WESTON FL 33327
Andrew Aromando officer: Chief Operating Officer C/O AMBRX BIOPHARMA INC., 10975 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
Cormorant Private Healthcare Fund Iii Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Global Healthcare Master Fund, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Bihua Chen 10 percent owner C/O CORMORANT ASSET MANAGEMENT, LP, 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116